SV

Street Verdict

Analyst Scorecard

CONCORDBIO · NSE

Concord Biotech Limited

₹548.2

-1.47% (-₹8.2)

Prev. close

₹556.4

Volume

1,28,839

Delivery %

57.4%

As of

20 Nov 2026

Price history

₹548.2-₹1,017.5 (-64.99%) · 3M
18 Aug 2026 → 20 Nov 2026
6008001,0001,2001,40018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Concord Biotech Limited

Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Ankur Vaid

Headquarters

Ahmedabad

Employees

1,624

Key stats

Market cap

₹13,715.18 Cr

P/E ratio (TTM)

49.1

Dividend yield

0.61%

EPS (TTM)

₹13.36

Beta (1Y · daily vs NIFTY 50)

0.99

Beta (5Y · monthly vs NIFTY 50)

1.63

Shares float

5.41 Cr

EPS · quarter ended Sept 2026

₹6.65

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr₹0%10%20%30%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).

02 · Earnings Per Share (EPS)

010203040₹FY23FY24FY25FY26

03 · Dividend Profile

0246₹0%10%20%30%21 Jun 2403 Sept 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-100 Cr0 Cr100 Cr200 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹830.63 Cr₹1,016.94 Cr₹1,200.09 Cr₹1,055.07 Cr
EBITDA
——₹380.56 Cr₹465.34 Cr₹550.78 Cr₹425.99 Cr
₹235.00 Cr₹175.00 Cr₹240.09 Cr₹308.10 Cr₹371.64 Cr₹260.91 Cr
Diluted EPS
——₹22.95₹29.13₹35.65₹25.17

Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2024 could not be checked against the company's own annual report: this page shows ₹308.10 Cr while the annual report gives ₹304.73 Cr (1.1% apart).

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,183.00 Cr₹1,313.00 Cr₹1,514.00 Cr₹1,701.00 Cr₹2,034.00 Cr₹2,232.00 Cr
——₹31.55 Cr₹9.74 Cr₹2.97 Cr₹2.32 Cr
Stockholders' equity
₹1,000.00 Cr₹1,104.00 Cr₹1,290.00 Cr₹1,526.00 Cr₹1,812.00 Cr₹2,017.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹167.00 Cr₹207.00 Cr₹246.00 Cr₹265.00 Cr₹245.00 Cr₹267.00 Cr
Investing cash flow
——₹-157.95 Cr₹-154.61 Cr₹-159.99 Cr₹-142.72 Cr
₹31.00 Cr₹-100.00 Cr₹-85.00 Cr₹-99.00 Cr₹-99.00 Cr₹-113.00 Cr
Capital expenditure
₹-204.00 Cr₹-156.00 Cr₹-145.00 Cr₹-86.00 Cr₹-111.00 Cr₹-95.00 Cr
End cash position
——₹3.50 Cr₹15.14 Cr₹90.45 L₹12.19 Cr

Investing cash flow, Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 23–Jun 26(12Q)
Promoter44.08%
Public55.92%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Concord Biotech Limited₹12,845.82 Cr₹655.546.06.3712.9%0.00-11.3%-54.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

CONCORDBIO

Concord Control Systems Ltd (BOM:543619) (Q2 2027) Earnings Call Highlights: Revenue Nearly ...

Yahoo Finance · 11 days ago

CONCORDBIO

Concord Biotech Limited says expansion cut H1 margin by 480 bps

Multibagg AI · 18 days ago